-
1
-
-
77956419239
-
-
Moreno-Otero R, Albillos A, Bañares R, Cuervas-Mons V, Medina J, editors. Acción Médica SA. Madrid
-
Tarantino G, Craxi A. Reversibility of fibrosis. Immunology and the liver: Inflammation, repair and therapies. In: Moreno-Otero R, Albillos A, Bañares R, Cuervas-Mons V, Medina J, editors. Acción Médica SA. Madrid, 2006:201-6.
-
(2006)
Reversibility of fibrosis. Immunology and the liver: Inflammation, repair and therapies
, pp. 201-206
-
-
Tarantino, G.1
Craxi, A.2
-
2
-
-
42949130108
-
Diagnosis and quantification of fibrosis
-
Manning D.S., Afdhal N.H. Diagnosis and quantification of fibrosis. Gastroenterology 2008, 134:1670-1681.
-
(2008)
Gastroenterology
, vol.134
, pp. 1670-1681
-
-
Manning, D.S.1
Afdhal, N.H.2
-
3
-
-
13544268721
-
Antifibrotic therapy in chronic liver disease
-
Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:95-107.
-
(2005)
Clin Gastroenterol Hepatol
, vol.3
, pp. 95-107
-
-
Rockey, D.C.1
-
4
-
-
54549119172
-
Current and future anti-fibrotic therapies for chronic liver disease
-
Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008, 12:939-962.
-
(2008)
Clin Liver Dis
, vol.12
, pp. 939-962
-
-
Rockey, D.C.1
-
5
-
-
33751248252
-
Direct and indirect evidence for the reversibility of cirrhosis
-
Serpaggi J., Carnot F., Nalpas B., Canioni D., Guéchot J., Lebray P., et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006, 37:1519-1526.
-
(2006)
Hum Pathol
, vol.37
, pp. 1519-1526
-
-
Serpaggi, J.1
Carnot, F.2
Nalpas, B.3
Canioni, D.4
Guéchot, J.5
Lebray, P.6
-
6
-
-
33344467649
-
Management of chronic hepatitis B virus infection: a new era of disease control
-
Farrell G.C., Teoh N.C. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006, 36:100-113.
-
(2006)
Intern Med J
, vol.36
, pp. 100-113
-
-
Farrell, G.C.1
Teoh, N.C.2
-
7
-
-
48249112996
-
Treatment of hepatitis B virus infection: present and future
-
Planas R., Morillas R.M. Treatment of hepatitis B virus infection: present and future. Gastroenterol Hepatol 2008, 31:349-355.
-
(2008)
Gastroenterol Hepatol
, vol.31
, pp. 349-355
-
-
Planas, R.1
Morillas, R.M.2
-
8
-
-
40949140557
-
Pharmacological agents for the treatment of chronic hepatitis B
-
Sánchez-Tapias J.M. Pharmacological agents for the treatment of chronic hepatitis B. Gastroenterol Hepatol 2008, 31:120-128.
-
(2008)
Gastroenterol Hepatol
, vol.31
, pp. 120-128
-
-
Sánchez-Tapias, J.M.1
-
9
-
-
34147150694
-
Reversal of liver cirrosis: a desirable clinical outcome and its pathogenic background
-
Bortolotti F., Guido M. Reversal of liver cirrosis: a desirable clinical outcome and its pathogenic background. J Pediatr Gastroenterol Nutr 2007, 44:401-406.
-
(2007)
J Pediatr Gastroenterol Nutr
, vol.44
, pp. 401-406
-
-
Bortolotti, F.1
Guido, M.2
-
10
-
-
34147149667
-
Reversibility of cirrosis in HIV/HBV coinfection
-
Mallet V.O., Dhalluin-Venier V., Verkarre V., Correas J.M., Chaix M.L., Virad J.P., et al. Reversibility of cirrosis in HIV/HBV coinfection. Antivir Ther 2007, 12:279-283.
-
(2007)
Antivir Ther
, vol.12
, pp. 279-283
-
-
Mallet, V.O.1
Dhalluin-Venier, V.2
Verkarre, V.3
Correas, J.M.4
Chaix, M.L.5
Virad, J.P.6
-
11
-
-
0037221907
-
Histological outcome during long-term lamivudina therapy
-
Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Gardner S., et al. Histological outcome during long-term lamivudina therapy. Gastroenterology 2003, 124:105-117.
-
(2003)
Gastroenterology
, vol.124
, pp. 105-117
-
-
Dienstag, J.L.1
Goldin, R.D.2
Heathcote, E.J.3
Hann, H.W.4
Woessner, M.5
Gardner, S.6
-
12
-
-
0035190894
-
Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection
-
Pohl A., Behling C., Oliver D., Kilani M., Monson P., Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001, 96:3142-3146.
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 3142-3146
-
-
Pohl, A.1
Behling, C.2
Oliver, D.3
Kilani, M.4
Monson, P.5
Hassanein, T.6
-
13
-
-
0036242165
-
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
-
Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
-
(2002)
Gastroenterology
, vol.122
, pp. 1303-1313
-
-
Poynard, T.1
McHutchison, J.2
Manns, M.3
Trepo, C.4
Lindsay, K.5
Goodman, Z.6
-
14
-
-
0041664940
-
Reversal of cirrhosis: Evidence-based Medicine?
-
Desmet V.J., Roskams T. Reversal of cirrhosis: Evidence-based Medicine?. Gastroenterology 2003, 125:629-630.
-
(2003)
Gastroenterology
, vol.125
, pp. 629-630
-
-
Desmet, V.J.1
Roskams, T.2
-
15
-
-
63049107827
-
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
-
Suzuki Y., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Hosaka T., et al. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?. J Gastroenterol Hepatol 2009, 24:429-435.
-
(2009)
J Gastroenterol Hepatol
, vol.24
, pp. 429-435
-
-
Suzuki, Y.1
Suzuki, F.2
Kawamura, Y.3
Yatsuji, H.4
Sezaki, H.5
Hosaka, T.6
-
16
-
-
33645730480
-
Peg-interferon improves liver histology in patients with HbeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudina
-
HBV 99-01 Study Group
-
Van Zonneveld M., Zondervan P.E., Cakaloglu Y., Simon C., Akarca U.S., So T.M., et al. Peg-interferon improves liver histology in patients with HbeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudina. Liver Int 2006, 26:399-405. HBV 99-01 Study Group.
-
(2006)
Liver Int
, vol.26
, pp. 399-405
-
-
Van Zonneveld, M.1
Zondervan, P.E.2
Cakaloglu, Y.3
Simon, C.4
Akarca, U.S.5
So, T.M.6
|